Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Friedreich’s Ataxia in 28 Major Markets
Friedreich’s ataxia (FA) is a rare genetic neurodegenerative disorder with the majority of cases involving expansion of a trinucleotide sequence in the gene coding for the protein fraxatin. Symptoms usually appear during childhood or adolescence as unsteadiness of gait which progresses into inability to walk independently within a few years, alongside other signs and symptoms. There are also cases of late-onset FA in which symptoms appear in middle age. Untreated FA results in limited life expectancy with death occurring due to multisystem complications and trauma sequelae, although the current therapies have significantly improved the average survival of FA patients.
This report provides the current prevalent population for FA across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Austria, Switzerland, Ireland, Greece, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, FA patients grouped by genetic features and symptoms have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of FA include:
• Left ventricular hypertrophy
• Supraventricular tachycardias
• Diabetes
• Scoliosis
• Cognitive deficits
• Affective disorders
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global FA market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of FA and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of FA patients.
• Identification of FA patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of FA patients.
Epiomic Epidemiology Series: Friedreich’s Ataxia Forecast in 28 Major Markets 2018–2028
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR FRIEDREICH’S ATAXIA
• FEATURES OF FRIEDREICH’S ATAXIA PATIENTS
• SIGNS AND SYMPTOMS OF FRIEDREICH’S ATAXIA PATIENTS
• COMORBIDITIES OF FRIEDREICH’S ATAXIA PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Prevalence of Friedreich’s ataxia, total (000s)
• Table 2. Prevalence of Friedreich’s ataxia, males (000s)
• Table 3. Prevalence of Friedreich’s ataxia, females (000s)
• Table 4. Patients with Friedreich's ataxia by number of GAA repeats, total (000s)
• Table 5. Friedreich's ataxia patients with gait ataxia, total (000s)
• Table 6. Friedreich's ataxia patients with limb ataxia, total (000s)
• Table 7. Friedreich's ataxia patients with dysarthria, total (000s)
• Table 8. Friedreich's ataxia patients with cardiomyopathy, total (000s)
• Table 9. Friedreich's ataxia patients with scoliosis, total (000s)
• Table 10. Friedreich's ataxia patients with diabetes, total (000s)
• Table 11. Friedreich's ataxia patients with visual loss, total (000s)
• Table 12. Abbreviations and acronyms used in the report
• Table 13. USA prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 14. USA prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 15. Canada prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 16. Canada prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 17. France prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 18. France prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 19. Germany prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 20. Germany prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 21. Italy prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 22. Italy prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 23. Spain prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 24. Spain prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 25. UK prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 26. UK prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 27. Poland prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 28. Poland prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 29. Netherlands prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 30. Netherlands prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 31. Belgium prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 32. Belgium prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 33. Norway prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 34. Norway prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 35. Sweden prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 36. Sweden prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 37. Denmark prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 38. Denmark prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 39. Finland prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 40. Finland prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 41. Austria prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 42. Austria prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 43. Switzerland prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 44. Switzerland prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 45. Ireland prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 46. Ireland prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 47. Greece prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 48. Greece prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 49. Russia prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 50. Russia prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 51. Turkey prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 52. Turkey prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 53. Japan prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 54. Japan prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 55. China prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 56. China prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 57. South Korea prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 58. South Korea prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 59. India prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 60. India prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 61. Australia prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 62. Australia prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 63. Brazil prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 64. Brazil prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 65. Mexico prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 66. Mexico prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
• Table 67. Argentina prevalence of Friedreich’s ataxia by 5-yr age cohort, males (000s)
• Table 68. Argentina prevalence of Friedreich’s ataxia by 5-yr age cohort, females (000s)
